Abbott Laboratories is presenting investors with a nuanced value proposition as its dividend yield approaches a ten-year peak while the stock contends with the financial effects of a major acquisition and legal setbacks. Shares are trading near $83 after a pullback following an earnings report, lifting the yield above 3% on an annual $2.52 payout.
The contrast is stark: Abbott has raised its dividend for 54 consecutive years and recently paid its 408th consecutive quarterly dividend, a streak that traces back to 1924. That record of dividend reliability is prompting some market participants to view the current yield as an uncommon buying opportunity. At the same time, the share price reflects two persistent headwinds cited by investors and analysts - the integration of the $21 billion Exact Sciences acquisition and nearly $500 million in upheld legal judgments.
Legal developments have been particularly visible in recent weeks. A Chicago jury awarded at least $70 million to four mothers who said Abbott failed to disclose that a cow milk-based infant formula intended for premature infants could cause necrotizing enterocolitis, a serious bowel disease. The jury split the award into $53 million in compensatory damages and $17 million in punitive damages. Jurors concluded Abbott knew of the risk but continued marketing the product to hospital intensive care units.
Abbott has publicly said it strongly disagrees with the verdict and plans to appeal, arguing that medical experts and regulators regard the products as safe and necessary. The recent ruling marks Abbott’s second trial loss in the infant formula litigation; the company now faces more than 1,700 related suits, with 784 pending in federal court in Illinois and the remainder in state courts, largely in Illinois.
Analysts at Jefferies have weighed in on the litigation outlook, characterizing the ongoing necrotizing enterocolitis, or NEC, litigation involving Abbott and Reckitt Benckiser as a manageable risk even as the number of legal battles grows. Jefferies’ analysts suggested a potential settlement range of $2 billion to $7 billion, while maintaining a base-case liability estimate for Abbott of $1 billion to $2 billion. That base-case figure represents less than 2% of the company’s market capitalization, according to the brokerage.
Jefferies noted divergent outcomes between state and federal proceedings. State courts in Illinois and Missouri have produced several substantial plaintiff verdicts, including a recent award against Abbott of roughly $95 million in compensatory damages and about $400 million in punitive damages. By contrast, federal multidistrict litigation proceedings have largely gone the defendants’ way, with a 3-1 record favoring Abbott and Reckitt in MDL cases to date.
The brokerage also highlighted a tactical timeline: a second wave of MDL bellwether trials scheduled over the next six to nine months could provide a natural opportunity for settlement talks. Jefferies emphasized that Abbott appears financially able to handle a settlement if necessary, pointing to an approximate $7.3 billion cash balance and steady cash generation.
Regulators and public health bodies have also been part of the public discussion. Jefferies’ summary observed that agencies including the FDA, CDC and NIH have stated there is no conclusive evidence directly linking cow’s milk-based formula to NEC, and that prematurity is considered the principal driver of the disease.
For investors focused on income, the combination of a yield above 3% and a long history of dividend increases is an attractive data point. Yet that income characteristic must be weighed against the potential financial exposure from ongoing litigation and the strategic and financial demands of integrating a large acquisition. The market’s recent reaction - pushing the yield to a near-decade high - reflects that balancing act as shareholders and analysts parse the path forward.
Bottom line: Abbott’s durable dividend track record and a yield topping 3% are drawing value-oriented attention, but a $21 billion acquisition and a complex, multi-jurisdictional wave of infant-formula litigation are key uncertainties that investors are factoring into the stock price.